By investigating the impact of vitexin on the STAT3 signaling pathway and key cancer markers, researchers have demonstrated that vitexin can successfully disrupt the sustained activation of JAK1, JAK2, and STAT3 in hepatocellular carcinoma (HCC) cells. Here, STAT3 is linked to hepatocellular carcinoma.